Current oligonucleotide manufacturing processes are unsustainable for future demand - GemBio aims to build what conventional processes can’t.
What does the future of therapeutics look like?
At GemBio, we believe it lies in oligonucleotide therapies, and we're building a reimagined manufacturing process to power it.
GemBio's proprietary manufacturing platform is designed to enable mass adoption of oligonucleotide medicines.
Designed for scalability, it delivers greater production capacity compared to conventional methods, enabling more doses per year, reducing production bottlenecks.
Powered by our ClarityCapture™ purification technology, our resin-free manufacturing platform delivers exceptional performance and high-purity products with consistent CMC profiles across all scales.
We work closely with therapeutic developers to reduce clinical translation risks and accelerate their path to the clinic.
